The primary therapeutic role of Primolut-Depot, a long-acting synthetic progestin, is centered on providing strong hormonal support in contexts where the body's natural progesterone levels are either insufficient or require pharmacological reinforcement. This is commonly used in two distinct therapeutic domains.

Prophylactic Management of Recurrent Preterm Birth

Primolut-Depot is commonly used to help manage the risk of recurrent spontaneous preterm birth in women who have a documented history of delivering a baby too early. This is applied in clinical settings that involve acute or unstable symptom patterns related to uterine instability. The medication provides supportive relief by addressing this instability and generally helps lower the risk of this complication recurring. It supports the maintenance of uterine quiescence to assist with prolongation of gestation. This therapeutic benefit supports the patient during difficult episodes by easing the impact of the condition.

Management of Progesterone-Deficient Gynecological States

The medication is also applied across domains where systemic hormonal imbalance affects reproductive function. Key indications include the absence of menstrual bleeding (amenorrhea) and functional issues like corpus luteum insufficiency. In these contexts, Primolut-Depot assists with supporting a return to regular function. Its benefit is to promote the necessary transformation of the uterine lining, supporting the restoration of a stable menstrual cycle and addressing conditions where functional stability becomes affected.

Quick Fact: Relief for Hormonal Imbalance and Uterine Instability

Primolut-Depot plays a role in managing symptoms related to both high-risk pregnancy maintenance and assisting with chronic gynecological deficits associated with progesterone shortage.

Eligibility and Non-Eligibility for Primolut-Depot

Official regulatory information defines strict conditions for the use of Primolut-Depot (Norethisterone Enantate injection), primarily through absolute exclusions known as contraindications.

---

Populations Who Must Not Use This Medicine (Contraindications):

• Pregnancy and Lactation: The medicine is strictly contraindicated if pregnancy is known or suspected, or during lactation.
• Vascular/Thrombotic Disease: Individuals with a current or history of arterial or venous thromboembolic disorders (such as deep vein thrombosis, pulmonary embolism, stroke, or heart attack) must not use this medicine. This includes conditions that signal an increased risk, like diabetes with vascular damage.
• Hepatic and Malignant Conditions: Use is contraindicated in the presence of severe liver disease until liver function normalizes, a history of liver tumors (benign or malignant), and known or suspected sex-hormone-dependent malignancies (e.g., of the breast or genital organs).
• Hypersensitivity: A known allergy to the active substance or any other component of the injection is an exclusion.

---

Age and Condition-Specific Considerations:

• The injection is not intended for use in children and is typically indicated only after menarche.
• Close medical supervision is required for patients with pre-existing conditions such as diabetes mellitus, a history of psychic depression, epilepsy, or migraine, with the medicine needing immediate discontinuation if severe symptoms develop or recur.

Interactions with Other Medicines and Products

Official regulatory documents define the interaction profile of Primolut-Depot based on its potential to be affected by, or affect, other medicines and specific laboratory tests. These interactions often relate to effects on liver enzymes.

Key Interaction Domains

The following domains summarize the essential interaction information:

• Hepatic Enzyme Inducers: Medicines that increase the clearance of sex hormones, primarily through liver enzyme induction, are documented to potentially reduce the therapeutic efficacy of Primolut-Depot. This class includes certain anti-epileptics (e.g., phenytoin, carbamazepine, barbiturates), anti-tuberculosis drugs (e.g., rifampicin), and the herbal product St. John's wort.
• Antiviral Combination Therapy: Co-administration with specific antiviral medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir is explicitly documented as contraindicated.
• Altered Metabolism of Concomitant Drugs: Sex steroids, such as those in Primolut-Depot, may interfere with the metabolism of certain other drugs, leading to changes in their plasma concentrations. An example of a drug whose concentration may be affected is the immunosuppressant cyclosporine.
• Laboratory Tests: The use of this drug is officially noted to influence the results of various laboratory tests, including those for biochemical parameters of liver, thyroid, adrenal, and renal function, as well as coagulation/bleeding indices and lipid fractions. These influences require consideration when interpreting test results.

Primolut-Depot, a prodrug, undergoes hydrolysis following intramuscular injection to release its active component, norethisterone. Norethisterone functions primarily as a progestogen receptor (PR) agonist, exhibiting high affinity for the intracellular PR, which is a ligand-activated transcription factor.

Upon binding, the activated hormone-receptor complex translocates into the cell nucleus. This complex subsequently interacts with specific DNA sequences, termed Progesterone Response Elements (PREs), modulating the transcription of target genes. This genomic signaling pathway induces changes in protein synthesis within target tissues, including the endometrium, hypothalamus, and pituitary gland.

At the systemic level, the primary cascade involves negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. This action suppresses the pulsatile release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus and, consequently, the secretion of pituitary Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). The resultant decrease in gonadotropin levels inhibits follicular development and prevents the LH surge necessary for ovulation.

Concurrently, norethisterone induces a secretory transformation in the estrogen-primed endometrium, and a distinct physiological consequence is the alteration of cervical mucus to a thicker, less permeable state.

Primolut-Depot, which contains the progestogen norethisterone enanthate (NET-EN), is administered solely as a deep intramuscular injection by a healthcare professional.

Injection Method and Site

The injection must be delivered slowly into a large muscle, typically the upper outer quadrant of the buttock (gluteal muscle), or alternatively, the upper arm (deltoid muscle). This method is crucial for the medication to form a depot, which allows for the gradual release of the active substance into the bloodstream for sustained therapeutic effect. After the injection, a plaster may be applied to the site to help prevent any solution from leaking out.

Dosage and Schedule

The required dosage and injection schedule are determined by the specific medical condition being treated, such as contraception or certain gynecological disorders.

For contraception, the first injection is generally given within the first five days of a menstrual cycle, and subsequent injections are typically repeated every eight weeks (two months) to maintain continuous protection. Adhering strictly to the prescribed injection intervals is essential for the effectiveness of the treatment. If the interval is missed or significantly extended, an alternative barrier method of contraception should be used.

Indication Example	Recommended Injection Frequency
Contraception	Typically every 8 weeks

Note: A thorough medical history and physical examination, including a blood pressure check and gynecological assessment, must be conducted by your healthcare provider before starting treatment and monitored regularly throughout the course of use.

Primolut-Depot: Recent Clinical Evidence

Clinical research has focused on the synthetic progestin component of Primolut-Depot (Hydroxyprogesterone Caproate, 17-OHPC), particularly regarding its former use in pregnancy and its action in gynecological contexts.

Evaluation in Pregnancy Outcomes

Recent, large-scale randomized controlled trials and subsequent meta-analyses have examined whether 17-OHPC may be associated with a reduced risk of recurrent premature birth in selected pregnant women. Key findings indicate that studies did not find a difference between the use of 17-OHPC and placebo (a non-active treatment) in preventing recurrent premature delivery or associated complications in newborns. In light of these results, the effectiveness of 17-OHPC for this indication is considered limited by some regulatory bodies.

Research into Long-Term Effects

Epidemiological studies have sought to understand the long-term profile of individuals who were exposed to 17-OHPC in the womb during the 1950s and 1960s. Data from this research suggested a possible, though unconfirmed, increased risk of certain types of cancer in adulthood compared with those who were not exposed to the medication. It is important to note that the study has limitations and the possible risk is not conclusively confirmed. Regulatory reviews have considered these long-term data alongside efficacy data.

Other Uses and Mechanism

Research has explored the use of the drug in certain gynecological and fertility disorders. For these uses, data on effectiveness are currently limited and findings vary across different studies. The action of 17-OHPC is thought to relate to its interaction with progesterone receptors, which plays a role in regulating the reproductive system and maintaining the uterine lining.

Common questions about Primolut-Depot (FAQ)

---

Q: What is Primolut-Depot?

A: Primolut-Depot is an injectable medication that contains hydroxyprogesterone caproate, a synthetic progestogen hormone.

---

Q: What is Primolut-Depot used for?

A: It is used in women for various gynecological and obstetric conditions. These uses may include:

• Reducing the risk of preterm birth (early delivery) in women with a history of spontaneous preterm birth.
• Management of certain menstrual disorders, such as primary and secondary amenorrhea (absence of menstruation).
• Management of infertility due to corpus luteum insufficiency.

---

Q: How is Primolut-Depot administered?

A: Primolut-Depot is given as a deep intramuscular (IM) injection into a muscle, typically in the gluteal area (buttock) or the upper arm, by a healthcare professional.

---

Q: What are the common side effects of Primolut-Depot?

A: Common side effects may include reactions at the injection site, such as pain, swelling, or a nodule. Other possible side effects include:

• Nausea
• Headache
• Dizziness
• Fatigue
• Mood changes
• Weight gain
• Breast tenderness
• Urticaria (hives) or pruritus (itching)

---

Q: Are there any specific warnings or precautions associated with Primolut-Depot?

A: Yes. Primolut-Depot should be used with caution, and its use is generally not recommended in patients with certain conditions. These may include:

• A history of hormone-sensitive cancers.
• Severe liver disease or unresolved abnormal liver function.
• A history of thromboembolic disorders (blood clots).
• Caution is also needed for patients with conditions like diabetes or cardiovascular disease.

It is essential to discuss your complete medical history with your healthcare provider before starting treatment.

---

Q: Can Primolut-Depot affect blood sugar levels?

A: Yes, Primolut-Depot may affect blood sugar levels. Patients with diabetes should have their blood sugar monitored regularly while using this medication, as it may require an adjustment to their diabetes treatment plan.

---

Q: Can Primolut-Depot cause skin discoloration?

A: Chloasma (skin discoloration, often on the face) may occasionally occur, especially in women who have had chloasma during pregnancy in the past. If you have a tendency toward chloasma, you should avoid exposure to the sun or ultraviolet (UV) radiation while receiving Primolut-Depot.

How to Store and Dispose of Primolut-Depot

Official regulatory guidelines strictly define the storage and disposal requirements for Primolut-Depot (Hydroxyprogesterone Caproate Injection).

Storage Requirement	Condition
Temperature	Store at controlled room temperature (20 C to 25 C).
Prohibited Conditions	Do not refrigerate or freeze the medicine.
Protection	Keep the vial upright in its original box to protect it from light.
Child Safety	Store the product out of the sight and reach of children.

Stability and Disposal

After the initial puncture of a multi-dose vial, any unused portion must be discarded within 28 days (or 5 weeks, depending on the formulation) to ensure stability. For disposal, used needles, syringes, and auto-injector devices must be immediately placed in a designated sharps disposal container. Unused or expired medication should be returned via a drug take-back program.